# Questions, Answered From the Literature > Questions — Research Peptide Fundamentals Research Peptides — Peptide Coalition — Cited answers to the questions readers actually ask about Research Peptide Fundamentals research peptides — BPC-157, CJC-1295, semaglutide, thymosin alpha-1 and PT-141 — from an independent review desk. **READER QUESTIONS** Short answers with their sources attached. Where the honest answer is that nobody knows, that is what appears here. ## What is a 'research peptide', and is it a real pharmacological category? No. It is a supply-chain description, not a pharmacological one. The phrase denotes a peptide sold for laboratory use, labelled not for human consumption, and distributed outside the pharmaceutical approval system. It carries no information at all about mechanism, evidence or risk. The five compounds on this site prove the point: semaglutide is an approved medicine with outcome trials in more than seventeen thousand participants [15]; bremelanotide is approved in the United States for one narrow indication [27]; thymalfasin is approved in over thirty-five countries but not the United States [19]; CJC-1295 and BPC-157 are approved nowhere. All five circulate through research-supply channels under identical labelling. ## What does BPC-157 do in the body? In animal models it acts as a cytoprotective and repair-promoting agent, and the effect most consistently linked to it is angiogenesis — the growth of new blood vessels into injured tissue. The best-characterised route is up-regulation and internalisation of the VEGF receptor 2 with downstream VEGFR2-Akt-eNOS signalling [4]. The foundational work reduced gastric ulcer area in rats and accelerated healing [5]. In humans, essentially none of this has been tested: a 2025 review found only three small pilot studies and concluded the compound should be regarded as investigational [2]. ## Is BPC-157 a growth hormone? No. BPC-157 is a fifteen-residue fragment derived from a protein in human gastric juice, and it has no structural or functional relationship to growth hormone. The confusion may arise from one reported mechanism: in cultured tendon fibroblasts BPC-157 has been described as sensitising growth hormone receptor signalling, meaning the cells respond more readily to growth hormone that is already present. That is a modulatory effect on an existing pathway, not the release or supply of a hormone. The compound in this review that genuinely raises growth hormone is [CJC-1295](/cjc-1295), which acts on the pituitary [9][10]. ## Does BPC-157 damage the liver? The published human data do not show liver injury, but the dataset is far too small to answer the question properly. The first-in-human intravenous safety pilot administered doses up to 20 mg to two healthy adults and reported no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two participants cannot establish hepatic safety. The accurate position is the one the 2025 review takes: with only a handful of small uncontrolled human reports in existence, the real balance of benefit and risk in people is unknown [2]. ## What is CJC-1295, and what does it do? CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone, built on the first twenty-nine residues of human growth-hormone-releasing factor with four amino-acid substitutions that block enzymatic degradation. In its long-acting DAC form it also carries a linker that bonds covalently to serum albumin [12]. It binds the GHRH receptor on pituitary somatotrophs and stimulates the pulsatile release of growth hormone, which raises hepatic IGF-1. In healthy adults, single subcutaneous doses raised mean growth hormone two- to ten-fold for six days or more and IGF-1 for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days [9]. ## Is CJC-1295 safe? That question cannot be answered from the published record, because the record is too thin to answer it. CJC-1295 is not approved for human use anywhere, and its human evidence consists of a small number of early pharmacology studies [9][10] with no long-term or large trials in healthy adults. Several mechanism-based concerns are documented: sustained IGF-1 elevation and its epidemiological association with modestly increased risk of certain cancers; fluid retention and nerve-compression effects following from growth hormone's action on renal sodium and water handling; reduced insulin sensitivity, since growth hormone is glucose-sparing; and immunogenicity, which the FDA cited in 2024 briefing materials as part of the basis for not recommending the substance for the 503A compounding bulks list. The original development programme was discontinued. ## How much CJC-1295 should I take? This desk does not answer that question, for anyone, in any form. It reads and summarises literature; it does not practise medicine, and CJC-1295 has no approved human indication and therefore no approved dose to report. What can be stated is what published studies administered: single subcutaneous doses of 30 or 60 micrograms per kilogram in one healthy-adult pharmacology study [9], and 60 or 90 micrograms per kilogram in another [10]. Those are descriptions of what investigators gave under study conditions, not recommendations, and most dosing protocols circulating online are not derived from controlled human trials at all. ## What is semaglutide, and how does it work for weight loss? Semaglutide (Ozempic, Wegovy, Rybelsus) is a thirty-one-residue acylated analogue of the gut hormone GLP-1, modified so that it resists the enzyme DPP-4 and binds reversibly to serum albumin — the structural basis for once-weekly dosing rather than the roughly two-minute survival of the native hormone. Its weight effect is primarily central rather than digestive: it reaches appetite circuitry in the hypothalamic arcuate nucleus and the brainstem area postrema, activating anorexigenic POMC and CART neurons and inhibiting orexigenic NPY and AgRP neurons, which reduces food intake and shifts food preference without lowering energy expenditure. In the STEP 1 trial, once-weekly 2.4 mg produced a mean body-weight change of minus 14.9 per cent at week 68 against minus 2.4 per cent with placebo [16]. ## What is thymosin alpha 1 used for? Its studied uses cluster in immune settings where the immune response has either collapsed or run away. The largest body of trial work is in sepsis, where results are mixed: the ETASS trial in 361 patients with severe sepsis found 28-day mortality of 26.0 per cent against 35.0 per cent in controls, a difference that did not reach conventional significance [22], while the much larger phase 3 TESTS trial in 1,106 adults found no difference at all, 23.4 per cent against 24.1 per cent, hazard ratio 0.99 [18]. It has also been studied in severe COVID-19, where a retrospective review of 76 patients reported reduced mortality and restoration of exhausted T cells [20], and it is described in oncology as an immunostimulatory adjuvant alongside chemotherapy and immunotherapy in melanoma, hepatocellular carcinoma and lung cancer [21]. ## Is thymosin alpha 1 FDA-approved? No. Thymosin alpha-1 is not approved for marketing in the United States. The synthetic peptide, thymalfasin, is approved as a drug in more than thirty-five countries [19], and some US orphan-drug designations have existed historically for specific indications, but a designation is not a marketing approval. US availability is limited to investigational and compounding contexts, and the FDA has evaluated related bulk substances for compounding without endorsing them. This is one of the clearest cases in the review of regulatory status being a fact about jurisdictions rather than a verdict on evidence — the compound is approved in dozens of countries and its most rigorous trial is negative [18]. ## What is PT-141, and what does the PT-141 peptide do? PT-141 is bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, closed by a lactam bridge. It activates central melanocortin receptors, chiefly MC4R, in the hypothalamus and limbic system, and is thought to engage dopaminergic circuits governing sexual desire. It is not a PDE-5 inhibitor and does not act on vascular smooth muscle, and it does not act through the hypothalamic-pituitary-gonadal axis or raise testosterone. A randomised crossover fMRI study in 31 premenopausal women found MC4R agonism increased sexual desire for up to 24 hours with altered processing of erotic stimuli [24]. It is approved in the United States only for acquired, generalised hypoactive sexual desire disorder in premenopausal women, given as a 1.75 mg subcutaneous dose as needed [27]. ## Why does this site organise five unrelated peptides around half-life? Because it is the only axis on which they are genuinely comparable, and because it predicts more than it has any right to. These five share no receptor, no tissue and no therapeutic area, so a comparison of what they do is an exercise in listing. A comparison of how long they last is not: it runs forward into the dosing format, the study design, the reachable endpoints, and the timing of the adverse effects. Semaglutide's once-weekly format is what made a 17,604-participant outcome trial operationally possible [15]; PT-141's few-hour clearance is what made its programme an as-needed episodic design [25][27]; thymosin alpha-1's five-to-seven-day course is why it was tested against 28-day mortality [18][19]. The site is honest about the boundary — duration says nothing about what a compound does, or about whether its evidence is any good. --- Peptide Coalition is an independent review desk that reads the peptide literature across classes for what recurs; it cites its sources, sells nothing, and prescribes nothing to anyone.